Compare Fresenius Kabi Onco. with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs FDC LTD. - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. FDC LTD. FRESENIUS KABI ONCO./
FDC LTD.
 
P/E (TTM) x 22.1 17.5 126.3% View Chart
P/BV x 3.1 2.4 131.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   FDC LTD.
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
FDC LTD.
Mar-18
FRESENIUS KABI ONCO./
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs176319 55.2%   
Low Rs79164 47.9%   
Sales per share (Unadj.) Rs37.761.6 61.1%  
Earnings per share (Unadj.) Rs5.19.9 51.2%  
Cash flow per share (Unadj.) Rs6.712.0 56.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.573.2 58.1%  
Shares outstanding (eoy) m158.23174.40 90.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.43.9 86.2%   
Avg P/E ratio x25.024.3 102.9%  
P/CF ratio (eoy) x18.920.2 93.8%  
Price / Book Value ratio x3.03.3 90.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13542,118 47.8%   
No. of employees `0001.25.5 20.8%   
Total wages/salary Rs m7032,167 32.5%   
Avg. sales/employee Rs Th5,176.21,943.7 266.3%   
Avg. wages/employee Rs Th610.4391.7 155.8%   
Avg. net profit/employee Rs Th699.6313.7 223.0%   
INCOME DATA
Net Sales Rs m5,96310,751 55.5%  
Other income Rs m18510 3.5%   
Total revenues Rs m5,98111,260 53.1%   
Gross profit Rs m1,4302,267 63.1%  
Depreciation Rs m258351 73.4%   
Interest Rs m-2614 -185.7%   
Profit before tax Rs m1,2162,411 50.4%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342671 51.0%   
Profit after tax Rs m8061,735 46.4%  
Gross profit margin %24.021.1 113.7%  
Effective tax rate %28.127.8 101.1%   
Net profit margin %13.516.1 83.7%  
BALANCE SHEET DATA
Current assets Rs m5,1027,213 70.7%   
Current liabilities Rs m2,3852,104 113.4%   
Net working cap to sales %45.647.5 95.9%  
Current ratio x2.13.4 62.4%  
Inventory Days Days15054 275.3%  
Debtors Days Days11328 408.6%  
Net fixed assets Rs m5,1486,865 75.0%   
Share capital Rs m158175 90.3%   
"Free" reserves Rs m6,55612,586 52.1%   
Net worth Rs m6,73212,761 52.8%   
Long term debt Rs m9526 15,870.0%   
Total assets Rs m10,38815,041 69.1%  
Interest coverage x-45.8173.2 -26.4%   
Debt to equity ratio x0.10 30,083.9%  
Sales to assets ratio x0.60.7 80.3%   
Return on assets %7.511.6 64.6%  
Return on equity %12.013.6 88.0%  
Return on capital %14.619.0 77.0%  
Exports to sales %74.512.3 603.4%   
Imports to sales %24.80-   
Exports (fob) Rs m4,4411,327 334.7%   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2981,889 280.5%   
Fx outflow Rs m1,7720-   
Net fx Rs m3,5251,889 186.6%   
CASH FLOW
From Operations Rs m1,2741,498 85.0%  
From Investments Rs m-1,204201 -598.8%  
From Financial Activity Rs m-196-1,694 11.6%  
Net Cashflow Rs m-12610 -1,226.2%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.7 6.4%  
FIIs % 9.6 7.5 128.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.0 47.9%  
Shareholders   42,599 23,730 179.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

FDC LTD. Announces Quarterly Results (3QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Feb 15, 2019 | Updated on Feb 15, 2019

For the quarter ended December 2018, FDC LTD. has posted a net profit of Rs 437 m (up 2.5% YoY). Sales on the other hand came in at Rs 3 bn (up 1.4% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY19); Net Profit Down 33.6% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, FDC LTD. has posted a net profit of Rs 431 m (down 33.6% YoY). Sales on the other hand came in at Rs 3 bn (down 12.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS